ScripIronwood Pharmaceuticals’ future looks uncertain after it revealed on 14 April that the US Food and Drug Administration indicated that it will need to see a confirmatory Phase III trial on top of data
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure
In VivoWalking through the halls of the St. Francis Westin Hotel during the J.P. Morgan Global Health Conference, one can’t help but notice the growing presence of East Asians. Yet, when it comes to the high
ScripDespite missing the primary endpoint of a Phase II trial testing solengepras (CVN424) in early, untreated Parkinson’s disease, Cerevance pointed to positive numerical trends on several key secondary e